To evaluate the effect of CD8α on tumor control, the authors administered CD8α+ and CD8α– CD56dim NK cells in a xenogenic K562 leukemia model and observed lower tumor burden in the CD8α– NK cell treatment cohort. This evidence concerns the gene CD8A and leukemia.